Role of Pre-procedural C-reactive Protein Level in the Prediction of Major Adverse Cardiac Events in Patients Undergoing Percutaneous Coronary Intervention: a Meta-analysisof Longitudinal Studies

详细信息    查看全文

• 作者：Singh-baniya Bibek (1)
  Yong Xie (2) (4)
  Jia-jia Gao (2) (4)
  Zhi Wang (3)
  Jing-feng Wang (2) (4)
  Deng-feng Geng (2) (4)
  
  1. Department of Cardiology ; Shahid Gangalal National Heart Center ; Kathmandu ; Nepal
  2. Department of Cardiology ; Sun Yat-sen Memorial Hospital ; Sun Yat-sen University ; No. 107 West Yanjiang Road ; Guangzhou ; 510120 ; China
  4. Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology ; Sun Yat-sen University ; Guangzhou ; 510120 ; China
  3. Department of Anesthesiology ; Sun Yat-sen Memorial Hospital ; Guangzhou ; 510120 ; China
  
• 关键词：pre ; procedural CRP level ; major adverse cardiac events ; percutaneous coronary intervention ; coronary artery disease
• 刊名：Inflammation
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：38
• 期：1
• 页码：159-169
• 全文大小：910 KB
• 参考文献：1. Thompson, D., M.B. Pepys, and S.P. Wood. 1999. The physiological structure of human C-reactive protein and its complex with phosphocholine. / Structure 7(2): 169鈥?77. CrossRef
  2. Pepys, M.B., and G.M. Hirschfield. 2003. C-reactive protein: a critical update. / Journal of Clinical Investigation 111(12): 1805鈥?812. CrossRef
  3. Macy, E.M., T.E. Hayes, and R.P. Tracy. 1997. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. / Clinical Chemistry 43(1): 52鈥?8.
  4. Rost, N.S., P.A. Wolf, C.S. Kase, M. Kelly-Hayes, H. Silbershatz, J.M. Massaro, R.B. D鈥橝gostino, C. Franzblau, and P.W. Wilson. 2001. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. / Stroke 32(11): 2575鈥?579. CrossRef
  5. Pearson, T.A., G.A. Mensah, R.W. Alexander, J.L. Anderson, R.O. Cannon 3rd, M. Criqui, Y.Y. Fadl, S.P. Fortmann, Y. Hong, G.L. Myers, N. Rifai, S.C. Smith Jr., K. Taubert, R.P. Tracy, F. Vinicor, and Centers for Disease Control and Prevention; American Heart Association. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. / Circulation 107(3): 499鈥?11. CrossRef
  6. Batine, M.S., et al. 2007. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. / Circulation 115: 1528鈥?536. CrossRef
  7. Berlin, J.A., M.P. Longnecker, and S. Greenland. 1993. Meta-analysis of epidemiologic dose-response data. / Epidemiology 4(3): 218鈥?28. CrossRef
  8. Stroup, D.F., J.A. Berlin, S.C. Morton, I. Olkin, G.D. Williamson, D. Rennie, D. Moher, B.J. Becker, T.A. Sipe, and S.B. Thacker. 2000. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. / JAMA 283(15): 2008鈥?012. CrossRef
  9. de Winter, R.J., G.S. Heyde, K.T. Koch, J. Fischer, J.P. van Straalen, M. Bax, C.E. Schotborgh, K.J. Mulder, G.T. Sanders, J.J. Piek, and J.G. Tijssen. 2002. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. / European Heart Journal 23(12): 960鈥?66. CrossRef
  10. Park, D.W., C.W. Lee, S.C. Yun, Y.H. Kim, M.K. Hong, J.J. Kim, S.W. Park, and S.J. Park. 2007. Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. / Heart 93(9): 1087鈥?092. CrossRef
  11. Rittersma, S.Z., R.J. de Winter, K.T. Koch, C.E. Schotborgh, M. Bax, G.S. Heyde, J.P. van Straalen, K.J. Mulder, J.G. Tijssen, G.T. Sanders, and J.J. Piek. 2004. Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement. / Clinical Chemistry 50(9): 1589鈥?596. CrossRef
  12. Yip, H.K., C.L. Hang, C.Y. Fang, Y.K. Hsieh, C.H. Yang, W.C. Hung, and C.J. Wu. 2005. Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. / Chest 127(3): 803鈥?08. CrossRef
  13. Razzouk, L., P. Muntner, S. Bansilal, A.S. Kini, A. Aneja, J. Mozes, O. Ivan, M. Jakkula, S. Sharma, and M.E. Farkouh. 2009. C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. / American Heart Journal 158(2): 277鈥?83. CrossRef
  14. Dibra, A., J. Mehilli, S. Braun, M. Hadamitzky, H. Baum, J. Dirschinger, H. Sch眉hlen, A. Sch枚mig, and A. Kastrati. 2003. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. / American Journal of Medicine 114(9): 715鈥?22. CrossRef
  15. Magadle, R., I. Hertz, H. Merlon, P. Weiner, I. Mohammedi, and D. Robert. 2004. The relation between preprocedural C-reactive protein levels and early and late complications in patients with acute myocardial infarction undergoing interventional coronary angioplasty. / Clinical Cardiology 27(3): 163鈥?68. CrossRef
  16. Ishii, H., T. Toriyama, T. Aoyama, H. Takahashi, T. Amano, M. Hayashi, M. Tanaka, Y. Kawamura, Y. Yasuda, Y. Yuzawa, S. Maruyama, S. Matsuo, T. Matsubara, and T. Murohara. 2009. Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis. / Circulation. Cardiovascular Interventions 2(6): 513鈥?18. CrossRef
  17. Veselka, J., S. Proch谩zkov谩, R. Duchonov谩, I. Homolov谩, and D. Tesar. 2005. Relationship of C-reactive protein to adverse cardiovascular events in patients treated by percutaneous coronary intervention for stable angina pectoris. / International Heart Journal 46(2): 195鈥?04. CrossRef
  18. Iijima, R., R.A. Byrne, G. Ndrepepa, S. Braun, J. Mehilli, P.B. Berger, A. Sch枚mig, and A. Kastrati. 2009. Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. / Heart 95(2): 107鈥?12. CrossRef
  19. Schoos, M.M., H. Kelb忙k, K.F. Kofoed, L. K酶ber, L. Kl酶vgaard, S. Helqvist, T. Engstr酶m, K. Saunam盲ki, E. J酶rgensen, L. Holmvang, and P. Clemmensen. 2011. Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. / American Journal of Cardiology 107(11): 1597鈥?603. CrossRef
  20. Ortolani, P., A. Marzocchi, C. Marrozzini, T. Palmerini, F. Saia, N. Taglieri, F. Baldazzi, S. Silenzi, M.L. Bacchi-Reggiani, P. Guastaroba, R. Grilli, and A. Branzi. 2008. Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. / European Heart Journal 29(10): 1241鈥?249. CrossRef
  21. Delhaye, C., G. Maluenda, K. Wakabayashi, I. Ben-Dor, G. Lemesle, S.D. Collins, A.I. Syed, R. Torguson, K. Kaneshige, Z. Xue, W.O. Suddath, L.F. Satler, K.M. Kent, J. Lindsay, A.D. Pichard, and R. Waksman. 2010. Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation. / American Journal of Cardiology 105(6): 826鈥?32. CrossRef
  22. Gao, F., Y.J. Zhou, X. Zhu, Z.J. Wang, S.W. Yang, and H. Shen. 2011. C-reactive protein and the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. / American Journal of Nephrology 34(3): 203鈥?10. CrossRef
  23. Jeong, Y.H., S.W. Lee, C.W. Lee, M.K. Hong, J.J. Kim, S.W. Park, S.J. Park, D.W. Park, and Y.H. Kim. 2008. Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction. / Clinical Cardiology 31(12): 572鈥?79. CrossRef
  24. Walter, D.H., S. Fichtlscherer, M. Sellwig, W. Auch-Schwelk, V. Sch盲chinger, and A.M. Zeiher. 2001. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. / Journal of the American College of Cardiology 37(3): 839鈥?46. CrossRef
  25. Hong, Y.J., M.H. Jeong, O.Y. Park, W. Kim, J.H. Kim, Y.K. Ahn, J.G. Cho, B.H. Ahn, S.P. Suh, J.C. Park, S.H. Kim, and J.C. Kang. 2003. The role of C-reactive protein on the long-term clinical outcome after primary or rescue percutaneous coronary intervention. / Korean Journal of Internal Medicine 18(1): 29鈥?4.
  26. Buffon, A., G. Liuzzo, L.M. Biasucci, P. Pasqualetti, V. Ramazzotti, A.G. Rebuzzi, F. Crea, and A. Maseri. 1999. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. / Journal of the American College of Cardiology 34(5): 1512鈥?521. CrossRef
  27. Chew, D.P., D.L. Bhatt, M.A. Robbins, M.S. Penn, J.P. Schneider, M.S. Lauer, E.J. Topol, and S.G. Ellis. 2001. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. / Circulation 104(9): 992鈥?97. CrossRef
  28. Karha, J., A.A. Bavry, V. Rajagopal, M.R. Henderson, S.G. Ellis, and S.J. Brener. 2006. Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent. / American Journal of Cardiology 98(5): 616鈥?18. CrossRef
  29. Heeschen, C., C.W. Hamm, J. Bruemmer, and M.L. Simoons. 2000. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. / Journal of the American College of Cardiology 35(6): 1535鈥?542. CrossRef
  30. Tomoda, H., and N. Aoki. 2000. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. / American Heart Journal 140(2): 324鈥?28. CrossRef
  31. Choi, D.H., K.W. Park, H.M. Yang, H.Y. Lee, J.S. Park, H.J. Kang, Y.J. Kim, B.K. Koo, B.H. Oh, Y.B. Park, and H.S. Kim. 2011. Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents. / International Journal of Cardiology 149(2): 174鈥?81. CrossRef
  32. Hong, Y.J., M.H. Jeong, S.Y. Lim, S.R. Lee, K.H. Kim, I.S. Sohn, H.W. Park, J.H. Kim, W. Kim, Y. Ahn, J.G. Cho, J.C. Park, and J.C. Kang. 2005. Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting. / Circulation Journal 69(12): 1477鈥?483. CrossRef
  33. Palmerini, T., A. Marzocchi, C. Marrozzini, P. Ortolani, F. Saia, L. Bacchi-Reggiani, S. Virz矛, S. Gianstefani, and A. Branzi. 2005. Preprocedural levels of C-reactive protein and leukocyte counts predict 9-month mortality after coronary angioplasty for the treatment of unprotected left main coronary artery stenosis. / Circulation 112(15): 2332鈥?338. CrossRef
  34. Zhou, Y.F., G. Csako, J.T. Grayston, S.P. Wang, Z.X. Yu, M. Shou, M. Leon, and S.E. Epstein. 1999. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. / American Journal of Cardiology 84(5): 595鈥?98. CrossRef
  35. Gaspardone, A., F. Crea, F. Versaci, F. Tomai, A. Pellegrino, L. Chiariello, and P.A. Gioffr猫. 1998. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. / American Journal of Cardiology 82(4): 515鈥?18. CrossRef
  36. Haque, M.M., M. Ullah, M.S. Alam, S.U. Ulabbi, and R. Uddin. 2011. Pre-procedural C-reactive protein level predicts in-hospital outcome in percutaneous coronary intervention. / Cardiovascular Journal 4(1): 32鈥?1.
  37. Zairis, M.N., J.A. Ambrose, A.G. Lyras, M.A. Thoma, P.K. Psarogianni, P.G. Psaltiras, A.D. Kardoulas, G.P. Bibis, E.G. Pissimissis, P.C. Batika, M.C. DeVoe, A.A. Prekates, S.G. Foussas, and GENERATION Study Group. 2004. C reactive protein, moderate alcohol consumption, and long term prognosis after successful coronary stenting: four year results from the GENERATION study. / Heart 90(4): 419鈥?24. CrossRef
  38. Angioi, M., I. Abdelmouttaleb, R.M. Rodriguez, I. Aimone-Gastin, C. Adjalla, J.L. Gu茅ant, and N. Danchin. 2001. Increased C-reactive protein levels in patients with in-stent restenosis and its implications. / American Journal of Cardiology 87(10): 1189鈥?193. CrossRef
  39. Herrmann, J., R.J. Lennon, G.W. Barsness, G.S. Sandhu, R. Gulati, P.J. Best, P. Sorajja, J.F. Bresnahan, V. Mathew, M.R. Bell, and A. Prasad. 2012. High sensitivity C-reactive protein and outcomes following percutaneous coronary intervention in contemporary practice. / Circulation. Cardiovascular Interventions 5(6): 783鈥?90. CrossRef
  40. Park, D.W., S.W. Lee, S.C. Yun, H.G. Song, J.M. Ahn, J.Y. Lee, W.J. Kim, S.J. Kang, Y.H. Kim, C.W. Lee, S.W. Park, and S.J. Park. 2011. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. / Journal of the American College of Cardiology 58(25): 2630鈥?639. CrossRef
  41. Xu, H.Y., S.B. Qiao, J.F. Zhang, Q.T. Dong, and J.J. Li. 2012. Different impacts of C-reactive protein and lipid profile on coronary lesions following a percutaneous coronary intervention. / Coronary Artery Disease 23(3): 181鈥?87. CrossRef
  42. Ridker, P.M., N. Rifai, L. Rose, J.E. Buring, and N.R. Cook. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. / New England Journal of Medicine 347(20): 1557鈥?565. CrossRef
  43. Danesh, J., J.G. Wheeler, G.M. Hirschfield, S. Eda, G. Eiriksdottir, A. Rumley, G.D. Lowe, M.B. Pepys, and V. Gudnason. 2004. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. / New England Journal of Medicine 350(14): 1387鈥?397. CrossRef
  44. Valgimigli, M., M. Tebaldi, M. Borghesi, P. Vranckx, G. Campo, C. Tumscitz, E. Cangiano, M. Minarelli, A. Scalone, C. Cavazza, J. Marchesini, G. Parrinello, and PRODIGY Investigators. 2014. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia study). / JACC. Cardiovascular Interventions 7(1): 20鈥?8. CrossRef
  45. Mart铆n-Reyes, R., R. Moreno, A. S谩nchez-Recalde, F. Navarro, J. Franco, A. Pi帽ero, and J.L. Send贸n. 2012. Comparison of the safety between first- and second-generation drug eluting stents: meta-analysis from 19 randomized trials and 16,924 patients. / International Journal of Cardiology 160(3): 181鈥?86. CrossRef
  46. Li, J.J., Y. Ren, K.J. Chen, A.C. Yeung, B. Xu, X.M. Ruan, Y.J. Yang, J.L. Chen, and R.L. Gao. 2010. Impact of C-reactive protein on in-stent restenosis: a meta-analysis. / Texas Heart Institute Journal 37(1): 49鈥?7.
  47. Ridker, P.M. 2001. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. / Circulation 103(13): 1813鈥?818. CrossRef
  48. Lagrand, W.K., C.A. Visser, W.T. Hermens, H.W. Niessen, F.W. Verheugt, G.J. Wolbink, and C.E. Hack. 1999. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? / Circulation 100(1): 96鈥?02. CrossRef
  49. Mortensen, R.F. 2001. C-reactive protein, inflammation, and innate immunity. / Immunologic Research 24(2): 163鈥?76. CrossRef
  50. Cermak, J., N.S. Key, R.R. Bach, J. Balla, H.S. Jacob, and G.M. Vercellotti. 1993. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. / Blood 82(2): 513鈥?20.
  51. Fichtlscherer, S., G. Rosenberger, D.H. Walter, S. Breuer, S. Dimmeler, and A.M. Zeiher. 2000. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. / Circulation 102(9): 1000鈥?006. CrossRef
  52. Pasceri, V., J.T. Willerson, and E.T. Yeh. 2000. Direct proinflammatory effect of C-reactive protein on human endothelial cells. / Circulation 102(18): 2165鈥?168. CrossRef
  53. Hung, M.Y., K.H. Hsu, M.J. Hung, C.W. Cheng, and W.J. Cherng. 2010. Interactions among gender, age, hypertension and C-reactive protein in coronary vasospasm. / European Journal of Clinical Investigation 40(12): 1094鈥?103. CrossRef
  54. Hung, M.Y., K.H. Hsu, M.J. Hung, C.W. Cheng, L.T. Kuo, and W.J. Cherng. 2009. Interaction between cigarette smoking and high-sensitivity C-reactive protein in the development of coronary vasospasm in patients without hemodynamically significant coronary artery disease. / American Journal of the Medical Sciences 338(6): 440鈥?46. CrossRef
  55. Peisajovich, A., L. Marnell, C. Mold, and T.W. Du Clos. 2008. C-reactive protein at the interface between innate immunity and inflammation. / Expert Review of Clinical Immunology 4(3): 379鈥?90. CrossRef
  56. Hansson, G.K., P. Libby, U. Sch枚nbeck, and Z.Q. Yan. 2002. Innate and adaptive immunity in the pathogenesis of atherosclerosis. / Circulation Research 91(4): 281鈥?91. CrossRef
  57. Ridker, P.M., M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens. 1997. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. / New England Journal of Medicine 336(14): 973鈥?79. CrossRef
  58. Ridker, P.M., C.P. Cannon, D. Morrow, N. Rifai, L.M. Rose, C.H. McCabe, M.A. Pfeffer, and E. Braunwald. 2005. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. / New England Journal of Medicine 352(1): 20鈥?8. CrossRef
  59. Nissen, S.E., E.M. Tuzcu, P. Schoenhagen, T. Crowe, W.J. Sasiela, J. Tsai, J. Orazem, R.D. Magorien, C. O鈥橲haughnessy, P. Ganz, and Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. 2005. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. / New England Journal of Medicine 352(1): 29鈥?8. CrossRef
  60. Ridker, P.M., E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, R.J. Glynn, and JUPITER Study Group. 2008. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. / New England Journal of Medicine 359(21): 2195鈥?207. CrossRef
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Rheumatology
  Internal Medicine
  Pharmacology and Toxicology
  Pathology
  
• 出版者：Springer Netherlands
• ISSN：1573-2576

文摘

Numerous studies have reported the relation between pre-procedural C-reactive protein (CRP) levels and the risk of major adverse cardiac events (MACEs) in patients undergoing percutaneous coronary intervention (PCI). However, the results across the studies were inconsistent. The aim of this study was to evaluate the predictive effect of pre-procedural CRP levels and the risk of MACEs in patients undergoing PCI. Longitudinal studies on the association between pre-procedural CRP levels and MACEs were identified by electronic and manual searches. Summary risk ratios (RRs) and 95 % confidence intervals (CI) were calculated employing an inverse variance random-effects model irrespective of between-study heterogeneity. Thirty-three studies involving 34,367 patients with 4119 MACEs were included in this study. High CRP level was associated with increased incidences of MACEs, all-cause death, myocardial infarction, coronary revascularization, and clinical restenosis, with pooled RRs of 1.97 (95 % CI, 1.65, 2.35), 2.88 (95 % CI, 2.15, 3.86), 1.81 (95 % CI, 1.48, 2.21), 1.31 (95 % CI, 1.11, 1.56), and 1.45 (95 % CI, 1.07, 1.96), respectively. Dose-response analysis showed that every 1 mg/L increment in pre-procedural serum CRP level was associated with a significant 12 % increase in the risk of MACEs. In spite of heterogeneity across the included studies, this meta-analysis suggests that pre-procedural serum CRP level is a valuable predictor of MACEs in patients undergoing PCI.